No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.3x · 10Y median 2.5x · 44th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:01:15.048Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Biodesix, Inc. (BDSX) stock was $29.06 as of Oct 5, 2026, 4:00 PM EDT, up 4.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +273.1% · 3-year avg -9.3%/yr · 5-year avg -28.5%/yr
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States.
Medical - Diagnostics & Research · Louisville, CO
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
-0.75
Revenue Est.
$27.55M
Last Quarter Results
EPS
$-0.71
vs Estimate
$-0.90
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BDSX | $236.56M | $29.06 | +4.83% | +273.09% | -28.49% | N/A | N/A |
| 2BIOA | $239.45M | $6.36 | -3.78% | +13.30% | N/A | N/A | vs BDSX |
| 3AKBA | $244.25M | $0.91 | +5.26% | -67.65% | -20.07% | -20.53% | vs BDSX |
| 4GALT | $245.65M | $3.73 | -4.36% | -13.80% | +0.60% | +13.41% | vs BDSX |
| 5CAMP | $251.64M | $4.01 | +0.25% | +32.17% | N/A | N/A | vs BDSX |
| 6ALEC | $220.94M | $1.99 | +9.94% | -39.91% | -39.17% | N/A | vs BDSX |
forward FY estimate
N/A
$26.86M
vs Estimate
$26.03M
Consensus Rating
Based on 6 analysts
Average Price Target
$37.33
+28.5% upside
Low
$30.00
Current
$29.06
High
$41.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.76 | $-0.75 | $-0.73 | 5 |
| Quarter ending Dec 2026 | $-0.46 | $-0.43 | $-0.39 | 5 |
| Quarter ending Mar 2027 | $-0.65 | $-0.64 | $-0.63 | 3 |
| Quarter ending Jun 2027 | $-0.56 | $-0.54 | $-0.53 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.71 | $-2.67 | $-2.64 | 5 |
| FY 2027 | $-1.75 | $-1.67 | $-1.58 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $27.16M | $27.55M | $28.09M | 5 |
| Quarter ending Dec 2026 | $31.66M | $31.99M | $32.26M | 5 |
| Quarter ending Mar 2027 | $29.75M | $30.13M | $30.64M | 4 |
| Quarter ending Jun 2027 | $31.79M | $32.21M | $32.75M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $111.31M | $111.95M | $112.39M | 6 |
| FY 2027 | $134.13M | $134.62M | $135.14M | 6 |
